SWOG clinical trial number
SWOG-9011
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin's Disease
Closed
Phase
Accrual
90%
Published
Abbreviated Title
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin's Disease
Activated
04/15/1990
Closed
12/01/1995
Research committees
Lymphoma
Publication Information Expand/Collapse
2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial
1996
Single fraction high dose chemotherapy with or without total body irradiation (TBI) and an autologous bone marrow transplant (ABMT) for patients with relapsed/refractory Hodgkin's disease: High survival rate in chemoresistant disease. A Southwest Oncology Group (SWOG) trial.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase